A Critical Appraisal of Treatment for T[sub3]N0 Colon Cancer

Yo, In S.; Opelka, Frank G.; Bolton, John S.; Fuhrman, George M.
February 2001
American Surgeon;Feb2001, Vol. 67 Issue 2, p143
Academic Journal
The purpose of this study was to evaluate the impact of adjuvant chemotherapy on survival after surgery for T[sub 3]N[sub 0] colon cancer. All patients with node-negative (N[sub 0]) colon cancer with tumor invasion beyond the muscularis propria (T[sub 3]) treated with colectomy between 1982 and 1995 at a single institution were included. Patients were divided into two groups depending on postcolectomy treatment with or without adjuvant chemotherapy. Groups were evaluated to determine perioperative and pathologic variables that could potentially influence outcome and surveillance data to determine disease-free and overall survival. In 253 patients with T[sub 3]N[sub 0] colon cancer 226 remained under observation and 27 were treated with adjuvant chemotherapy. The groups were similar (P = not significant) when compared for tumor location, size, differentiation, number of nodes harvested, and transfusion requirements. Four of the 27 patients who received chemotherapy developed a recurrence (14.8%), whereas 22 of the 226 observation patients developed a recurrence (9.7%). Disease-free survival for the chemotherapy group at 5 years was 84 per cent and for the observation group 87 per cent. Statistical analysis (Mantel-Cox) showed no significant difference between the groups on the basis of survival (P = 0.3743). We conclude that resection alone is a highly effective treatment for T[sub 3]N[sub 0] colon cancer leaving limited opportunity for adjuvant chemotherapy to significantly impact survival. Adjuvant chemotherapy for T[sub 3]N[sub 0] colon cancer patients should be limited to patients enrolled in clinical trials designed to identify subgroups of T[sub 3]N[sub 0] colon cancer patients at a survival disadvantage or less toxic adjuvant chemotherapies.


Related Articles

  • Feasibility and short-term outcome of adjuvant FOLFOX after resection of colorectal liver metastases. Sakamoto, Yasuo; Beppu, Toru; Miyamoto, Yuji; Okabe, Hirohisa; Ida, Satoshi; Imai, Katsunori; Chikamoto, Akira; Watanabe, Masayuki; Takamori, Hiroshi; Baba, Hideo // Journal of Hepato -- Biliary -- Pancreatic Sciences;Mar2013, Vol. 20 Issue 3, p307 

    Background: The role of adjuvant chemotherapy for stage IV colorectal cancer has so far been under-investigated. The aim of this study was to assess the feasibility and short-term outcome of adjuvant chemotherapy with the FOLFOX regimen following liver resection for patients with colorectal...

  • Prolonged Survival of Patients with Metastatic Colorectal Cancer following First-Line Oxaliplatin-Based Chemotherapy with Molecular Targeting Agents and Curative Surgery. Shitara, Kohei; Matsuo, Keitaro; Kondo, Chihiro; Takahari, Daisuke; Ura, Takashi; Inaba, Yoshitaka; Yamaura, Hidekazu; Sato, Yozo; Kato, Mina; Kanemitsu, Yukihide; Komori, Koji; Ishiguro, Seiji; Sano, Tsuyoshi; Shimizu, Yasuhiro; Muro, Kei // Oncology;2011, Vol. 81 Issue 3/4, p167 

    Background: The ability of molecular targeting agents to improve overall survival (OS) in metastatic colorectal cancer (MCRC) patients who underwent oxaliplatin-based chemotherapy remains controversial. Methods: We retrospectively analyzed 331 patients with MCRC who underwent first-line...

  • Surgical Treatment of Cancer of the Colon or Rectum.  // Journal of Gastrointestinal Surgery;Sep2007, Vol. 11 Issue 9, p1200 

    The article focuses on the surgical removal treatment of cancer of the colon or rectum. It says that colorectal cancers are considered to begin from a series of genetic events resulting in precursor lesions like polyps. It mentions that patients with colon cancer and lymph node metastases (Stage...

  • Survival of Elderly Patients with Colon Cancer Treated with Chemotherapy. Sundararajan, V.; Mitra, N.; Jacobson, J.S.; Grann, V.R.; Heitjan, D.F.; Neugut, Al // Annals of Internal Medicine;3/5/2002, Vol. 136 Issue 5, pI19 

    Compares the survival rate of elderly patients with colon cancer treated with chemotherapy and chemotherapy with 5-flouroucaril (5-FU). Positive result of patients treated with chemotherapy and 5-FU; Implication of the study on the treatment of younger patients; Increase in the survival rate of...

  • Alternative Spliced Variants as Biomarkers of Colorectal Cancer. Qian Yi; Liling Tang // Current Drug Metabolism;Dec2011, Vol. 12 Issue 10, p966 

    Surgical resection and adjuvant therapy, which mainly involves 5-fluorouracil (5-FU), irinotecan (CPT-11), oxaliplatin (LOHP) chemotherapy and recently targeted therapy, are the most common treatments of colorectal cancer (CRC). As to improve the therapeutic efficacy and assist with therapeutic...

  • Initial safety report on the tolerability of modified FOLFOX6 as adjuvant therapy in patients with curatively resected stage II or III colon cancer (JFMC41-1001-C2: JOIN trial). Kotaka, Masahito; Yoshino, Takayuki; Oba, Koji; Shinozaki, Katsunori; Touyama, Tetsuo; Manaka, Dai; Matsui, Takanori; Ishigure, Kiyoshi; Hasegawa, Junichi; Inoue, Keiji; Goto, Koichi; Sakamoto, Junichi; Saji, Shigetoyo; Ohtsu, Atsushi; Watanabe, Toshiaki // Cancer Chemotherapy & Pharmacology;Jul2015, Vol. 76 Issue 1, p75 

    Purpose: Adjuvant FOLFOX is a widely accepted standard therapy for resected colon cancer. The incidence of grade 3-4 peripheral sensory neuropathy (PSN) was 12.4 and 5.7 % in the MOSAIC and Eastern MASCOT trials, while that of grade 3-4 allergic reactions (AR) was 2.9 and 3.1 %, respectively....

  • Metastatic Colorectal Cancer: Is Surgery Necessary? Schmidt, Charlie // JNCI: Journal of the National Cancer Institute;8/19/2009, Vol. 101 Issue 16, p1113 

    The article focuses on the surgical and chemotherapeutic approaches for the treatment of metastatic colorectal cancer. It states that doctor Philip Paty and his colleagues made use of chemotherapeutic drugs including 5-fluorouracil (5-FU) and irinotecan to shrink primary tumors before operating...

  • Focused preoperative patient stoma education, prior to ileostomy formation after anterior resection, contributes to a reduction in delayed discharge within the enhanced recovery programme. Younis, Jenan; Salerno, Gisella; Fanto, Daniela; Hadjipavlou, Marios; Chellar, Daniel; Trickett, Jonathan // International Journal of Colorectal Disease;Jan2012, Vol. 27 Issue 1, p43 

    Purpose: Stoma formation is a well-known cause for delayed discharge following colorectal surgery. This has been addressed by the enhanced recovery programme (ERP) preoperatively through stoma counselling sessions. These aim to promote independent stoma management post-operatively, thus...

  • Adjuvant Chemotherapy Use and Adverse Events Among Older Patients With Stage III Colon Cancer. Kahn, Katherine L.; Adams, John L.; Weeks, Jane C.; Chrischilles, Elizabeth A.; Schrag, Deborah; Ayanian, John Z.; Kiefe, Catarina I.; Ganz, Patricia A.; Bhoopalam, Nirmala; Potosky, Arnold L.; Harrington, David P.; Fletcher, Robert H. // JAMA: Journal of the American Medical Association;3/17/2010, Vol. 303 Issue 11, p1037 

    The article focuses on an observational study which evaluated adjuvant chemotherapy use and outcomes for older people with stage III colon cancer from well-defined population-based settings and health care systems. The study was conducted in five geographically defined regions in the U.S.,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics